Retention rates were 42.5 and 55.7 percent for preadolescent and adolescent subgroups after 24 months of treatment<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, March 17, 2022 (HealthDay News) — Daily oral perampanel is generally well tolerated, with favorable retention rates among patients with epilepsy aged 1 to younger than 18 years, according to a study recently published in the Journal of Child Neurology<\/em>.<\/p>\n Eric Segal, M.D., from the Hackensack University Medical Center in New Jersey, and colleagues reported an interim analysis of preadolescent and adolescent patients (aged 1 to younger than 12 years and aged 12 to younger than 18 years, respectively) from a retrospective phase 4 study. Data were obtained from medical records of 151 preadolescent and 183 adolescent patients with epilepsy initiating perampanel after Jan. 1, 2014.<\/p>\n The researchers found that following 24 months of perampanel, retention rates were 42.5 and 55.7 percent for the preadolescent and adolescent subgroups, respectively. Treatment-emergent adverse events occurred in 35.1 percent of preadolescent participants, with aggression, irritability, and somnolence the most common; treatment-emergent adverse events occurred in 42.6 percent of adolescent patients, with somnolence, aggression, and dizziness the most common.<\/p>\n “Our research shows that daily oral doses of perampanel are well tolerated and have favorable retention rates for pediatric patients,” Segal said in a statement. “These findings provide real-world insight into the effectiveness and safety of perampanel therapy and can inform shared decision-making discussions between pediatric epileptologists, patients, and parents.”<\/p>\n Several authors disclosed financial ties to pharmaceutical companies, including Eisai, which manufactures perampanel and funded the study.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n